Prossimo
My point of view on…
Gratuito
mer 25 nov 2026, 13:30–14:30 CET
Program
November 25th, 2026
2:30 pm – 5:00 pm (CET UTC+1)
2.30 – 2.40 | Welcome & Opening Remarks
2.40 | Adjuvant therapies for RCC and UCFernando Sabino Marques Monteiro (BRA)
3.00 | Achieving and managing complete remissions in RCCMaria T. Bourlon (MEX)
3.20 | Intensification and De-Intensification in mHSPCPasquale Rescigno (UK)
3.40 | Best setting for PARP inhibitors in mHSPC and mCRPCAndrey Soares (BRA)
4.00 | Primary refractory to immunotherapy and to ADC in RCC and UCMatteo Santoni (ITA)
4.20 | Perioperative and adjuvant approaches in UCJavier Molina-Cerrillo (SPN)
4.40 | Take home messages & Q&A
5.00 | Closing Remarks
Rationale
ARON Research Foundation ETS is a global non-profit dedicated to advancing research in genitourinary oncology. We bridge the gap between scientific discovery and clinical practice by fostering specialized education for healthcare professionals and championing equitable access to treatment through global healthcare reporting. This webinar will focus on the latest, practice-changing updates in the management of renal cell carcinoma (RCC), urothelial carcinoma (UC), and advanced prostate cancer (mHSPC/mCRPC). Leading international experts will share their unique perspectives on emerging therapeutic strategies, including modern adjuvant and perioperative approaches, PARP inhibitors, antibody-drug conjugates (ADCs), and mechanisms to overcome immunotherapy resistance. By exploring these cutting-edge advancements, the event aims to translate recent clinical trial data into optimized, real-world patient care630
Info
CME
Course ID 3282 - 497716 provides 3 Continuing Medical Education (CME) credits (ITALY ONLY).
Credit certification is subject to 100% full attendance of the training program and successful completion of the final assessment.
CME Provider
Alfa FCM - 3282info@alfafcm.com
Organizing Secretariat
Contattaci
- Accurate
- in••••o@acc••••s.it
Classificazioni
Categorie
- Webinar live